Search results
Sanofi Sales, Profit Beat Expectations
The Wall Street Journal· 5 days agoSanofi backed its full-year earnings guidance after it reported first-quarter profit ahead of consensus, with sales growth driven by continued strength...
Sanofi reports 1Q revenue increase, as sales of vaccines, Dupixent rise
WFMZ Eastern Pennsylvania and Western New Jersey· 5 days agoSanofi, a pharmaceutical company with Monroe County operations, reported a 2.4% gain in...
RSV vaccine boosts Monroe County's Sanofi Pasteur
WFMZ Eastern Pennsylvania and Western New Jersey· 5 days agoSanofi, a pharmaceutical company with Monroe County operations, reported a 2.4% gain in first-quarter revenue on Thursday, as sales of vaccines and the...
Sanofi (SNY) Rilzabrutinib Shows Benefit in Blood Disorder Study
Zacks via Yahoo Finance· 7 days agoSanofi's (SNY) BTK inhibitor, rilzabrutinib, demonstrates durable platelet response in the phase III...
Sanofi jumps as Q1 key profit measure tops estimates; Citi reiterates Buy By Investing.com
Investing.com· 5 days agoSanofi jumps as Q1 key profit measure tops estimates; Citi reiterates Buy
Greenleaf Trust Sells 10,451 Shares of Sanofi (NASDAQ:SNY)
ETF DAILY NEWS· 6 days agoGreenleaf Trust trimmed its stake in Sanofi (NASDAQ:SNY – Free Report) by 56.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities ...
AstraZeneca Flirts With A Breakout After Cancer Drug Sales Shine; Sanofi, Bristol Stocks Diverge
Investor's Business Daily· 5 days agoSanofi Stock: Dupixent Missed, But Solid In related news, Sanofi stock jumped 5.9% to 49.36 on its...
Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates
Zacks via Yahoo Finance· 4 days agoCap Pharmaceuticals Industry 5YR % Return Large Cap Pharmaceuticals Industry 5YR % Return Here’s how...
Novo Nordisk: Growth Is Still A Better Choice
GuruFocus.com via Yahoo Finance· 23 hours agoThe Danish pharmaceutical company is expected to release first-quarter financial results on May 5. Analysts forecast Novo Nordisk...financial metric is...
AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study By...
Investing.com· 5 days agoAbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
